Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Cellectar Biosciences, Inc.

Get SEC filing alerts via email and in your feed for Cellectar Biosciences, Inc.

CLRB

Cellectar Biosciences, Inc.

About Cellectar Biosciences, Inc.

Cellectar Biosciences is a late-stage biopharmaceutical company developing targeted cancer therapies using proprietary phospholipid ether drug conjugate (PDC) platform. Its focus is on radioconjugates delivering radioisotopes directly to cancer cells, including hematologic malignancies and solid tumors. The company’s core products, such as iopofosine, aim to improve efficacy and safety by minimizing off-target effects, targeting cancer stem cells, and expanding treatment options for rare and refractory cancers.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Cellectar Biosciences, Inc.

1
1
Cellectar Biosciences, Inc. Cellectar Biosciences Reports $5.7M Net Loss and Decreased Operating Expenses for Q1 2026

Via official filing (AI summary) | 21 days ago | 0 comments

2
1
Cellectar Biosciences, Inc. Cellectar Biosciences Reports $1.2M Revenue and $21.8M Net Loss in 2025 Fiscal Year

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Cellectar Biosciences, Inc. Cellectar Biosciences Reports 70% Reduction in Q3 Financial Losses

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Cellectar Biosciences, Inc. Cellectar Biosciences Reports Reduced Losses and Strategic Focus on Cancer Therapies

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Cellectar Biosciences, Inc. Cellectar Biosciences Reports 75% Reduction in Financial Losses for Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Cellectar Biosciences, Inc. Cellectar Biosciences Reports $44.6 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Cellectar Biosciences, Inc. Cellectar Biosciences Reports Improved Financial Position, Net Loss, and Clinical Progress in Recent 10-Q Filing

Via official filing (AI summary) | over 1 year ago | 0 comments

8
1
Cellectar Biosciences, Inc. Cellectar Biosciences Reports Improved Financials, Reduced Net Loss, and Progress in Cancer Treatment Clinical Trials

Via official filing (AI summary) | over 1 year ago | 0 comments